Pancreatic Cancer Research

ResearcherWenzhou Medical UniversityNo recent work listed

Bicheng Chen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5663-7065; OpenAlex author ID A5111926646. Sources: OpenAlex.

Their work

Papers
19 (first author 1, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
36
Papers, trials and grants by year

2014: 2 papers · 2015: none · 2016: 3 papers · 2017: 6 papers · 2018: 3 papers · 2019: 1 paper · 2020: 3 papers · 2021: 1 paper

Papers 19

  1. Periplocin inhibits the growth of pancreatic cancer by inducing apoptosis via AMPK-mTOR signaling. Co-author DOI 10.1002/cam4.3611↗
  2. KRT17 Functions as a Tumor Promoter and Regulates Proliferation, Migration and Invasion in Pancreatic Cancer via mTOR/S6k1 Pathway. Last author DOI 10.2147/cmar.s243129↗
  3. STRAP as a New Therapeutic Target for Poor Prognosis of Pancreatic Ductal Adenocarcinoma Patients Mainly Caused by TP53 Mutation. Co-author DOI 10.3389/fonc.2020.594224↗
  4. Upregulation of CENPM facilitates tumor metastasis via the mTOR/p70S6K signaling pathway in pancreatic cancer. Last author DOI 10.3892/or.2020.7673↗
  5. Baohuoside I Inhibits the Proliferation of Pancreatic Cancer Cells via mTOR/S6K1-Caspases/Bcl2/Bax Apoptotic Signaling. Co-author DOI 10.2147/cmar.s228926↗
  6. LncRNA-PVT1 promotes pancreatic cancer cells proliferation and migration through acting as a molecular sponge to regulate miR-448. Co-author DOI 10.1002/jcp.26072↗
  7. Brusatol Enhances the Chemotherapy Efficacy of Gemcitabine in Pancreatic Cancer via the Nrf2 Signalling Pathway. Co-author DOI 10.1155/2018/2360427↗
  8. Tyrphostin B42 attenuates trichostatin A-mediated resistance in pancreatic cancer cells by antagonizing IL-6/JAK2/STAT3 signaling. Co-author DOI 10.3892/or.2018.6241↗
  9. Brusatol inhibits growth and induces apoptosis in pancreatic cancer cells via JNK/p38 MAPK/NF-κb/Stat3/Bcl-2 signaling pathway. Co-author DOI 10.1016/j.bbrc.2017.04.133↗
  10. Dermokine contributes to epithelial-mesenchymal transition through increased activation of signal transducer and activator of transcription 3 in pancreatic can… Co-author DOI 10.1111/cas.13347↗
  11. The Lncrna-TUG1/EZH2 Axis Promotes Pancreatic Cancer Cell Proliferation, Migration and EMT Phenotype Formation Through Sponging Mir-382. Co-author DOI 10.1159/000479990↗
  12. HNRNPA2B1 regulates the epithelial-mesenchymal transition in pancreatic cancer cells through the ERK/snail signalling pathway. Co-author DOI 10.1186/s12935-016-0368-4↗
  13. Quercetin inhibits epithelial-mesenchymal transition, decreases invasiveness and metastasis, and reverses IL-6 induced epithelial-mesenchymal transition, expre… Co-author DOI 10.2147/ott.s136840↗
  14. Erratum: Isoorientin induces apoptosis, decreases invasiveness, and downregulates VEGF secretion by activating AMPK signaling in pancreatic cancer cells [Corri… Co-author DOI 10.2147/ott.s140829↗
  15. Interleukin-32α inactivates JAK2/STAT3 signaling and reverses interleukin-6-induced epithelial-mesenchymal transition, invasion, and metastasis in pancreatic c… Co-author DOI 10.2147/ott.s103581↗
  16. Isoorientin induces apoptosis, decreases invasiveness, and downregulates VEGF secretion by activating AMPK signaling in pancreatic cancer cells. Co-author DOI 10.2147/ott.s122653↗
  17. Sedum sarmentosum Bunge extract induces apoptosis and inhibits proliferation in pancreatic cancer cells via the hedgehog signaling pathway. First author DOI 10.3892/or.2016.4679↗
  18. Antitumor efficacy of α-solanine against pancreatic cancer in vitro and in vivo. Co-author DOI 10.1371/journal.pone.0087868↗
  19. Reversion of trichostatin A resistance via inhibition of the Wnt signaling pathway in human pancreatic cancer cells. Co-author DOI 10.3892/or.2014.3476↗

Closest collaborators

The 25 strongest of 36 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Mengtao Zhou · 10 shared papers, 2014–2018 · strength 0.65
  2. Chenlei Zheng · 4 shared papers, 2019–2020 · strength 0.45
  3. Dinglai Yu · 6 shared papers, 2016–2018 · strength 0.41
  4. Linxiao Sun · 3 shared papers, 2019–2021 · strength 0.41
  5. Chaohao Huang · 5 shared papers, 2016–2018 · strength 0.34
  6. Hongwei Sun · 4 shared papers, 2014–2018 · strength 0.28
  7. Yukai Xiang · 4 shared papers, 2017–2018 · strength 0.28
  8. Xince Huang · 4 shared papers, 2016–2017 · strength 0.28
  9. Zongjing Chen · 3 shared papers, 2014–2018 · strength 0.22
  10. Cheng Wang · 2 shared papers, 2019–2020 · strength 0.21
  11. Shengjie Dai · 3 shared papers, 2016–2017 · strength 0.20
  12. Yongheng Bai · 3 shared papers, 2014–2018 · strength 0.20
  13. Gangyin Xie · 1 shared paper, 2021 · strength 0.19
  14. Liang Zhao · 2 shared papers, 2017–2018 · strength 0.18
  15. Keqing Shi · 2 shared papers, 2018–2020 · strength 0.18
  16. Mengtao Zhou · 2 shared papers, 2016–2017 · strength 0.14
  17. Jie Zhang · 2 shared papers, 2017 · strength 0.14
  18. Tingting Ye · 2 shared papers, 2016–2017 · strength 0.14
  19. Ding Li · 1 shared paper, 2020 · strength 0.11
  20. Wenqian Huang · 1 shared paper, 2020 · strength 0.11
  21. Hongbao Yang · 1 shared paper, 2020 · strength 0.11
  22. Percy David Papa Akuetteh · 1 shared paper, 2020 · strength 0.11
  23. Shanshan Hu · 1 shared paper, 2020 · strength 0.11
  24. Qiyu Zhang · 1 shared paper, 2020 · strength 0.11
  25. Jingfeng Chen · 2 shared papers, 2014–2016 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.